HV Jain
Exploiting the synergy between carboplatin and ABT-737 in the treatment of ovarian carcinomas
Jain, HV; Richardson, A; Meyer-Hermann, M; Byrne, HM
Abstract
Platinum drug-resistance in ovarian cancers mediated by anti-apoptotic proteins such as Bcl-xL is a major factor contributing to the chemotherapeutic resistance of recurrent disease. Consequently, concurrent inhibition of Bcl-xL in combination with chemotherapy may improve treatment outcomes for patients. Here, we develop a mathematical model to investigate the potential of combination therapy with ABT-737, a small molecule inhibitor of Bcl-xL, and carboplatin, a platinum-based drug, on a simulated tumor xenograft. The model is calibrated against in vivo experimental data, wherein xenografts established in mice were treated with ABT-737 and/or carboplatin on a fixed periodic schedule. The validated model is used to predict the minimum drug load that will achieve a predetermined level of tumor growth inhibition, thereby maximizing the synergy between the two drugs. Our simulations suggest that the infusion-duration of each carboplatin dose is a critical parameter, with an 8-hour infusion of carboplatin given weekly combined with a daily bolus dose of ABT-737 predicted to minimize residual disease. The potential of combination therapy to prevent or delay the onset of carboplatin-resistance is also investigated. When resistance is acquired as a result of aberrant DNA-damage repair in cells treated with carboplatin, drug delivery schedules that induce tumor remission with even low doses of combination therapy can be identified. Intrinsic resistance due to pre-existing cohorts of resistant cells precludes tumor regression, but dosing strategies that extend disease-free survival periods can still be identified. These results highlight the potential of our model to accelerate the development of novel therapeutics such as BH3 mimetics.
Acceptance Date | Oct 23, 2013 |
---|---|
Publication Date | Jan 6, 2014 |
Journal | PLoS One |
Print ISSN | 1932-6203 |
Publisher | Public Library of Science |
Pages | e81582 - ? |
DOI | https://doi.org/10.1371/journal.pone.0081582 |
Keywords | algorithms, animals, biphenyl compounds, carboplatin, cell line, tumor, computer simulation, disease models, animal, drug resistance, neoplasm, drug synergism, female, humans, mice, models, biological, nitrophenols, ovarian neoplasms, piperazines, sulfona |
Publisher URL | http://dx.doi.org/10.1371/journal.pone.0081582 |
Files
Exploiting the synergy between carboplatin and ABT-737 in the treatment of ovarian carcinomas.pdf
(709 Kb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by/4.0/
You might also like
Ivermectin Augments the Anti-Cancer Activity of Pitavastatin in Ovarian Cancer Cells
(2023)
Journal Article
Identification of foods that affect the anti-cancer activity of pitavastatin in cells
(2022)
Journal Article
Synthesis and evaluation of thymoquinone analogues as anti-ovarian cancer agents
(2019)
Journal Article
Downloadable Citations
About Keele Repository
Administrator e-mail: research.openaccess@keele.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search